ME 23andMe
- 0.410
- +0.001+0.34%
23andMe News
Looking Into 23andMe Holding's Recent Short Interest
23andMe Holding's (NYSE:ME) short percent of float has fallen 6.06% since its last report. The company recently reported that it has 36.69 million shares sold short, which is 11.79% of all regular sha
Sector Update: Health Care Stocks Retreat Monday Afternoon
Health care stocks were declining Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down 0.1%. The iShares Biotechnology ETF (IBB) fell 0.3%. In
Express News | Canada and UK Privacy Authorities Have Launched Joint Investigation Into 23Andme Data Breach - Canada Authority
Street Color: 23andMe Faces Joint Probe From UK Information Commissioner's Office, Canada's Privacy Commissioner Office Over 2023 Data Breach
(Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is
23andMe Launches New Genetic Report on Bipolar Disorder
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variantsSOUTH SAN FRANCISCO, Calif., June 05, 2024
Why 23andMe Stock Tumbled 10% on Tuesday
Express News | 23Andme and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
Study aims to fill research gap and empower people through access to information about their healthSUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a
Express News | 23Andme Holding Co.: Tumor Cd200 Is Emerging as a Potential Biomarker Associated With 23Me-00610 Monotherapy Efficacy
Express News | 23Andme Holding Co.: 23Me-00610 Monotherapy Continues to Demonstrate Acceptable Safety and Tolerability
Express News | 23Andme Holding Co.: 23Me-00610 Monotherapy Demonstrates Preliminary Evidence of Clinical Benefit, Including One Confirmed Partial Response
Express News | 23Andme Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23Me-00610, Targeting Cd200R1, at the 2024 Asco Annual Meeting
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, Targeting CD200R1, at the 2024 ASCO Annual Meeting
– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response– 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerabi
23andMe | 10-K: Annual report
Largest Study on the LRRK2 Variant Leads to Discoveries About Health, Ancestry, and History
Findings from 23andMe research on Parkinson's disease published in BrainThe LRRK2 variant is strongly associated with symptoms of Parkinson's disease (PD) that are different from non-variant carriers
23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Struggling 23andMe Soars 15%+ Intraday on Fiscal Q4 Revenue Beat
Struggling 23andMe Soars 15%+ Intraday on Fiscal Q4 Revenue Beat
Q4 2024 23andMe Holding Co. Earnings Call
Earnings Call Summary | 23andMe(ME.US) Q4 2024 Earnings Conference
The following is a summary of the 23andMe Holding Co. (ME) Q4 2024 Earnings Call Transcript:Financial Performance:23andMe reported a Q4 revenue of $64 million and annual revenue of $220 million, a dec
Express News | 23Andme Holding Co. Shares up 2.9% Premarket After Q4 Results
Analysis
Price Target
No Data
